NEXT-GENERATION EGFR TKI H002 FROM REDCLOUD BIO COMPLETES FIRST DOSE IN NON-SMALL CELL LUNG CANCER
Aug. 29, 2022, SHANGHAI, CHINA RedCloud Bio (the "Company"), an innovative biotech company integrating structural pharmacology and computational approaches to advance small molecule drug discovery and development, announced completion of the first patient dosing for its next-generation EGFR TKI H002 in its H002-101CN study. The study is a multicenter phase I/IIa clinical trial in China for advanced NSCLC. H002 is a next-generation EGFR TKI discovered and developed by RedCloud Bio for treatment of prior EGFR TKI-resistant NSCLC, including those with C797S mutation.
Jun 17, 2021, Nanjing China - RedCloud Bio announced the completion of B round financing of RMB100 million, led by CO-WIN Ventures and followed by KAITAI Capital. Existing shareholders, Sherpa Capital, Dayou Capital and Dynamic Balance Investment participated.
This
round of financing will boost RedCloud Bio's development of small molecule drug
research platform based on structural pharmacology, molecular dynamics-based
structure optimization and accelerate the Company's IND process for its next
generation RGFR inhibitor.
Nov 30, 2019, Nanjing China - Dayou Capital and Sherpa Capital Invested in A Round Financing for RedCloud Bio
-
Support RedCloud Bio to establish a robust small molecule drug discovery
program centered around structural pharmacology approach
-
Fund the Company's research centers in Beijing and Shanghai
May 23, 2019, Beijing China - Top oncology journal - Cancer Discovery（IF=24.37）published the latest results by Michael Eck, Nathanael Gray and Pasi Janne from Dana-Farber/Harvard Cancer Center，for their work on allosteric inhibitor JBJ-04-125-02 based on the design of the first fourth generation EGFR inhibitor EAI045, became a hot topic in the industry.
As
one of the co-developers for world's first fourth generation EGFR inhibitor
EAI045, as well as a core team member in Michael Eck's group, Prof. Caihong Yun
revealed the status of next generation EGFR inhibitor to Chinese media for the
first time.
Contact Us
Nanjing | 307-311, Building No.9, 669-8 Xuanwu Avenue, Xuanwu District
Shanghai | Suite 901, 880 Xiangyang Road, Minhang District
Beijing | Suite 205, Building No.2, PKUCare Industrial Park,
Changping District
Website：https://www.redcloudbio.com
Email：IR@redcloudbio.com
Follow us on WeChat: RedCloudBio
2022 © RedCloudBio Co., Ltd. All Rights Reserved